Observational studyAlcoholism, clinical and experimental research2019
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder.
Observational study in Alcoholism, clinical and experimental research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.Alcoholism, clinical and experimental research · 2021Trial
- Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.Alcohol, clinical & experimental research · 2026Article
- Comparative effectiveness of gabapentin and pregabalin on reduction in alcohol use: A nationwide observational cohort study.medRxiv : the preprint server for health sciences · 2026Article
- Bridging Genomics and Pharmacoepidemiology to Expand Treatment Options for Alcohol Use Disorder.medRxiv : the preprint server for health sciences · 2026Article
- Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.The Journal of clinical investigation · 2025Article
- Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data.Addiction (Abingdon, England) · 2022Article
- Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.Drug and alcohol dependence · 2021Article
- Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis.Drug and alcohol dependence · 2020Article
- Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2020Article
- On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.Expert review of precision medicine and drug development · 2020Article
- Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies.Current opinion in psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCurrent medications for alcohol use disorder (AUD) have limited efficacy and utilization. Some clinical trials have shown efficacy for gabapentin among treatment-seeking individuals. The impact of gabapentin on alcohol consumption in a more general sample remains unknown.
methodsWe identified patients prescribed gabapentin for ≥180 consecutive days for any clinical indication other than substance use treatment between 2009 and 2015 in the Veterans Aging Cohort Study. We propensity-score matched each gabapentin-exposed patient with up to 5 unexposed patients. Multivariable difference-in-difference (DiD) linear regression models estimated the differential change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores during follow-up between exposed and unexposed patients, by baseline level of alcohol consumption and daily gabapentin dose. Analyses were stratified by AUD history. Clinically meaningful changes were a priori considered a DiD ≥1 point.
resultsAmong patients with AUD, AUDIT-C scores decreased 0.39 points (95% confidence interval [CI] 0.05, 0.73) more among exposed than unexposed patients (p < 0.03). Potentially clinically meaningful differences were observed among those with AUD and exposed to ≥1,500 mg/d (DiD 0.77, 95% CI 0.15, 1.38, p < 0.02). No statistically significant effects were found among patients with AUD at doses lower than 1,500 mg/d or baseline AUDIT-C ≥4. Among patients without AUD, we found no overall difference in changes in AUDIT-C scores, nor in analyses stratified by baseline level of alcohol consumption.
conclusionsPatients exposed to doses of gabapentin consistent with those used in clinical trials, particularly those with AUD, experienced a greater decrease in AUDIT-C scores than matched unexposed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.